News - December 17, 2020
Published on 8 December, the European Medicines Agency (EMA) and Heads of Medicines Agency (HMA) Joint Strategy looks into six strategic focus areas: (1) Availability and accessibility of medicines, (2) Digital tools and digital transformation, (3) Innovation, (4) Antimicrobial resistance, (5) Supply chain challenges, and… read more
News - December 14, 2020
According to the MHRA Guidance, up until 31 December 2021, medicines can be supplied from Great Britain (GB) to Northern Ireland (NI) with a “pragmatic approach” to applying EU rules on importation and unique identifier requirements. Outside of these two areas, medicines supplied to NI have… read more
Events & Meetings / News - December 2, 2020
Aware of the complex European policy landscape that will keep policymakers busy in the months to come, EUCOPE wanted to discuss the European innovation leadership in the pharmaceutical sector and discover how the European Union and Member States can support pharmaceutical innovation in Europe. On… read more
News - December 2, 2020
On 8 December, the European Alliance for Transformative Therapies, a broad alliance of Members of European Parliament, patient groups, European Reference Networks, academia and industry, will be officially launched in a virtual meeting from 16.00 to 17.30. The Alliance, supported by MEPs Claudia Gamon (RE,… read more
EUCOPE Resources / News - December 1, 2020
EUCOPE’s approach to the EU environment for the development of OMPs On 11 August 2020, the European Commission published its evaluation on the legislation for medicines for rare diseases and for children. In November this was followed by an Inception Impact Assessment outlining policy options… read more
Events & Meetings / News - November 27, 2020
On 30/11, the European Medicines Agency (EMA) will organise a virtual event to encourage early and efficient interactions with the regulators by highlighting pre-marketing support in medicine development in rare diseases. The meeting will highlight and explain existing tools in the context of early product development strategy…. read more
EUCOPE Resources / News / Press Releases - November 25, 2020
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
News - November 24, 2020
RARE Conversations Breakfast Briefing Impact of COVID-19 on Pharmaceutical Research and Development in Rare Diseases 3 December 2020 | 10.00 – 11.15 CET via Zoom Europe has long been at the forefront in healthcare and is home to many leading healthcare professionals, academia and… read more
News - November 24, 2020
In the follow-up of Commission President von der Leyen’s intention to shape a resilient European Health Union, the Commission services announced on 11 November the publication of a Communication on Building a European Health Union: Reinforcing the EU’s resilience for cross-border health threats accompanied by… read more
News - October 28, 2020
Sickle cell disease is one of the most prevalent genetic diseases in Europe. A recent report, commissioned by our member company Global Blood Therapeutics, use the latest data from 5 EU countries to draw recommendations to improve the life expectancy of people living with this… read more
